David Bruining, MD
Gastroenterology · Rochester, MNNPI 1750361788
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 59.2% of the total. 2023 is the largest year on record at $3,433, more than ten times the $71 reported in 2019.
Across 4 payments — averaging $1026.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$604
- Boston Scientific$71
Across 16 payments — averaging $9605.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Covidien LP$71K
- Takeda Pharmaceuticals U.S.A., Inc.$44K
- Astrazeneca UK Limited$39K
What the payments were for
- Consulting fees$2,43359%
- Speaking & faculty fees$1,60439%
- Food & beverage$712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 1 | $2,433 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $1,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $604 |
| Boston Scientific | 1 | $71 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,108 in reported general payments places this provider in the 75th percentile of 365 gastroenterology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 18 | $488,630 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $185 |
| Pantoprazole Sodium | 14 | $42 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Rochester
- John KisielRochester$856K
- Christopher GostoutRochester$299K
- Edward LoftusRochester$282K
- Alina AllenRochester$277K
- Todd BaronRochester$270K
- Sahil KhannaRochester$242K
- Joseph MurrayRochester$234K
- Andres AcostaRochester$224K
- David LarsonRochester$142K
- Ibrahim HanounehRochester$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.